PMN Stock Analysis: Can ProMIS Neurosciences Rebound From 52-Week Lows?
PMN stock is trading at fresh 52-week lows with a tiny market cap and extreme macro fear, leaving the near-term outlook bearish to neutral. Upside depends on clinical data, partnerships, and financing, making PMN a high-risk, speculative biotech trade rather than a core investment.